Journal
AAPS JOURNAL
Volume 25, Issue 4, Pages -Publisher
SPRINGER
DOI: 10.1208/s12248-023-00824-3
Keywords
anti-PD-1; checkpoint blockade; melanoma; resiquimod (RSQ); tumor microenvironment
Categories
Ask authors/readers for more resources
Melanoma, the deadliest form of skin cancer, can be treated with surgery. However, there are cases where surgery fails or is not an option. Immunotherapy, specifically immune checkpoint blockade like anti-PD-1, can be an effective alternative treatment. In this study, the combination of anti-PD-1 and the TLR-7/8 agonist RSQ showed promising results in prolonging the survival of melanoma-challenged mice. RSQ also demonstrated direct anti-proliferative effects on melanoma cells in vitro.
Melanoma is the deadliest form of skin cancer and surgery is currently the most effective treatment. However, there are situations where surgery fails or is not an option to treat melanoma patients. Immunotherapy such as immune checkpoint blockade (e.g., anti-PD-1) can be effective as an alternative treatment for melanoma patients; however, the percentage of melanoma patients that exhibit complete responses from anti-PD-1 monotherapy is low, and a hostile immunosuppressive tumor microenvironment may be at least partly responsible. Resiquimod (RSQ) is an imidazoquinolinamine derivative and TLR-7/8 agonist that could enhance the antitumor activity of immune checkpoint blockade when these agents are combined as a treatment for melanoma. Here, the effect of combining systemic anti-PD-1 and locally administered RSQ on the survival of melanoma-challenged mice was tested. Our results demonstrated that anti-PD-1 in combination with RSQ can significantly prolong the survival of melanoma-challenged mice, compared to untreated mice and mice treated with anti-PD-1 alone. In addition, the in vitro studies showed that RSQ can mediate a direct anti-proliferative effect on melanoma cells. In conclusion, the combination of RSQ and anti-PD-1 may be a promising treatment for melanoma patients, especially as both treatments have already been used independently to safely treat melanoma patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available